Spero Therapeutics reported third quarter 2026 financial results, ending the period with $107.9 million in cash and cash equivalents. The company is focused on advancing its in-licensed anti-CD40L antibody, SP001, toward a Phase 2 trial in IgG4-related disease expected to initiate in Q2 2027.
“We believe SP001 represents a compelling opportunity to address significant unmet medical needs across multiple immune-mediated diseases. With a strong financial position and the recent additions to our team that strengthen the capabilities needed to support our next stage of development, we believe we are well positioned to execute our clinical development strategy.”
Esther Rajavelu, President and Chief Executive Officer
Spero Therapeutics reported that the FDA approved GSK’s NDA resubmission for Utebzi in June 2026, shifting the company's focus to the development of SP001. As of November 6, 2026, the company had 58,264,577 shares of common stock outstanding and continues to rely on milestone payments and royalties from its GSK partnership to fund operations.
Spero Therapeutics Insider Esther Rajavelu Sells $42.5K of Stock
Esther Rajavelu sold 40,851 shares of Spero Therapeutics, Inc. at $1.04 a share, worth $42.5K in total on Nov 9, 2026. Shares held after the trade: 946,000 (-4.1%).
Patrick Vink, M.D. resigned from the Board of Directors effective November 10, 2026, after 11 years of service. To fill the vacancy, the Board appointed William Ho, M.D., Ph.D., a former RAPT Therapeutics executive, as a Class II director and member of the Development Committee. Dr. Ho will receive an annual cash retainer of $45,000 and was granted an option to purchase 100,000 shares of common stock.